Mallinckrodt inks deal to distribute generic drug addiction treatment

August 20, 2013 1:08 pm  • 

Mallinckrodt Pharmaceuticals announced Tuesday that it has entered into an agreement with New Jersey-based Amneal Pharmaceuticals to distribute a generic form of Suboxone, a drug used to treat opioid dependence.

The company, with U.S. headquarters in Hazelwood, is a major supplier of generic opioid dependence drugs used in addiction treatment centers.

Amneal makes the generic version of Suboxone at its manufacturing facility in Hauppauge, N.Y.

The collaboration is the first between the companies.

“The core competencies we have built during the course of our 145-year history, particularly our extensive distribution network and expertise in handling controlled substances, makes us an ideal partner for Amneal,” said Walt Kaczmarek, Mallinckrodt’s vice president and general manager for specialty generics, in a statement. “This agreement demonstrates our continued focus to unlock our potential and drive growth based on what we do well within our generic specialty pharmaceutical business.”

Earlier this summer Mallinckrodt was formally spun off from its parent, Dublin-based Covidien. Mallinckrodt has kept its legal headquarters in Dublin largely for tax reasons.

The company was founded in St. Louis as G. Mallinckrodt & Co. in 1867, and was acquired by Tyco International in 2000. Tyco spun off its health care division as Covidien in 2007. In 2011 Covidien announced it would spin off Mallinckrodt, making it a fully independent company again.

The company currently has about 2,500 employees in the area, and 5,500 worldwide. It manufactures branded and generic specialty pharmaceuticals, as well as products for X-ray imaging.

This entry was posted in Industry Updates, Manufacturers Updates and tagged , , . Bookmark the permalink.

Comments are closed.